 |
delta-9-tetrahydrocannabinol
Posted on 2008-Jun-12 at 04:37 - Post Comment
For some years the principal psychoactive ingredient of marijuana, delta-9-tetrahydrocannabinol (9-THC), has been available to healthcare providers in an oral form as dronabinol (trade name Marinol) for the treatment of emesis associated with cancer chemotherapy and for appetite stimulation in the treatment of AIDS wasting syndrome. The current debate centers primarily on the potential for other treatment indications and the claims that, when smoked, marijuana offers therapeutic advantages over the currently available oral form feminized cannabis seeds. As the Federal Government's principal biomedical research agency, the NIH believed that the public debate could benefit from an impartial examination of all the data available to date concerning these issues. As the claims for benefits were wide ranging, 10 major components of the NIH participated in the planning for the conference.
« Last Page :: Next Page »
|
|